Spain· ES:1151082001
GALAFOLD 123 MG CAPSULAS DURAS
A migalastat product containing migalastat, registered in Spain by Amicus Therapeutics Europe Limited. The same ATC class is registered in 16 of our 19 countries.
Checked against AEMPS CIMA (Spain) on
Informational only — not a medical device.
Where it is registered
Migalastat is registered in 16 of 19 countries.
Countries holding a registration under ATC A16AX14 (migalastat), each read from that country’s own register.
- This record: Spain, from AEMPS CIMA (Spain)
- 11 of them publish a price we can compare per daily dose
Migalastat · ATC A16AX14
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of migalastat costs, country by country.
Normalised to the WHO defined daily dose (61.5 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Migalastat · price per daily dose (61.5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$793.74
The record
At a glance
AEMPS CIMA (Spain)- Active substance
- migalastat
- Manufacturer
- Amicus Therapeutics Europe Limited
- Country
- Spain (ES)
- ATC code
- A16AX14
- ATC class
- Migalastat
- Defined daily dose
- 61.5 mg, O
- Reimbursed
- Not published by this register
- Source register
- AEMPS CIMA (Spain)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
1 interaction on record for migalastat.
Graded by severity as the source publishes them — 1 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Migalastat · interactions on record
1 record
- 1 moderate
Most severe, free to view
- Agalsidase betaA16AB04moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Migalastat in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumGalafold 123 mgAmicus Therapeutics Europe
- CanadaGALAFOLDAMICUS THERAPEUTICS CANADA INC.
- SwitzerlandGalafold
- CzechiaGALAFOLDAmicus Therapeutics Europe Limited, Dublin
- FinlandGalafoldAmicus Therapeutics Europe Limited
- FranceGALAFOLD 123 mg, géluleAMICUS THERAPEUTICS EUROPE (IRLANDE)
- United KingdomGalafold 123mg capsulesAmicus Therapeutics UK Operations Ltd
- IrelandGalafold 123 mg hard capsulesAmicus Therapeutics Europe Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Galafold
- Liechtenstein · Galafold
- Norway · Galafold
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of AEMPS CIMA (Spain). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3adc84c7-7c2a-4f2b-88e4-d74856604e5d GET /v1/drugs/3adc84c7-7c2a-4f2b-88e4-d74856604e5d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cpresc": "Diagnóstico Hospitalario",
"estado": "{\"aut\":1472462068000}",
"nregistro": "1151082001",
"substance": "migalastat"
}See everything about migalastat.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.